HOLLISTON, Mass., Sept. 24, 2013 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, today announced that its wholly-owned regenerative medicine device subsidiary, Harvard Apparatus Regenerative Technology, Inc., or HART, filed an amendment to its initial Form 10 Registration Statement ("Form 10") on September 20, 2013 with the U.S. Securities and Exchange Commission. The Form 10 relates to Harvard Bioscience's intentions to separate the regenerative medicine device business from Harvard Bioscience's profitable core life science research tools business.
The amendment to HART's Form 10 includes updated disclosures pertaining to the financial statements of the business, overview of the markets and industries in which it will operate, details regarding the company's management, competitive strengths, risk factors, and other matters. A copy of the amendment to the Form 10 is available at www.sec.gov under the name of Harvard Apparatus Regenerative Technology, Inc.
Completion of the spin-off is subject to a number of conditions, including the effectiveness of the Form 10, Private Letter Ruling from the IRS, execution of the Separation and Distribution Agreement between Harvard Bioscience and HART, solvency opinion, capital contribution of at least $15 million from Harvard Bioscience to HART, and other customary conditions. On June 28, 2013, Harvard Bioscience received a Supplemental Ruling to the Private Letter Ruling dated March 22, 2013 from the IRS to the effect that the spin-off will qualify as a transaction that is tax-free for U.S. federal income tax purposes.
Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, the intention to consummate the spin-off of Harvard Apparatus Regenerative Technology, Inc., the related Form 10 filing with the SEC and NASDAQ Capital Market listing and the tradability of the HART securities. These statements involve risks and uncertainties, including among other things, market and other conditions that may cause results to differ materially from the statements set forth in this press release. There can be no assurance that such statements and information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements and information. The forward-looking statements in this press release speak only as of the date of this press release. Harvard Bioscience expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.
For investor inquiries, please call (508) 893-8066. Press releases may be found on our web site, http://www.harvardbioscience.com.
The Harvard Bioscience, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6426
CONTACT: Jeffrey Duchemin Chief Executive Officer email@example.com David Green President firstname.lastname@example.org Tom McNaughton Chief Financial Officer email@example.com Tel: 508 893 8999 Fax: 508 892 6135
|HBIO Subsidiary Harvard Apparatus Regenerative Technology, Inc. Files Form 10 Registration Statement for Planned Spin-Off (2013/7/31)|
|HBIO Announces Details of Approved Spin-Off of Harvard Apparatus Regenerative Technology, Inc. (2013/10/16)|
|Hess Files Form 10 Registration Statement Related to Spin Off of Retail Business (2014/1/8)|
|Chesapeake Files Form 10 Registration Statement for Possible Spin-off of Chesapeake Oilfield Services (2014/3/17)|
|Demand Media Announces Filing of Form 10 Registration Statement for Planned Separation of Domain Name Services Business ()|
|TETRA Technologies, Inc. Files Annual Report On Form 10-K For The Year Ended December 31, 2013 (2014/3/3)|
|Harvard Bioscience Announces Allocation of Tax Basis for Spin-Off of Harvard Apparatus Regenerative Technology ()|
|Harvard Apparatus Regenerative Technology Files Pre-IND Meeting Documents and Orphan Biologics Application with U.S. Food and Drug Administration ()|
|Harvard Apparatus Regenerative Technology Reports Fourth Quarter and Year Ended December 31, 2013 Operating Results (2014/3/7)|
|Harvard Apparatus Regenerative Technology Profiled by Boston Globe and WBZ-AM CBS NewsRadio Boston (2013/11/21)|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.